N calculation for trial about PK superiority [Power / Sample Size]

posted by dshah  – India, 2022-09-02 13:52 (739 d 05:46 ago) – Posting: # 23262
Views: 2,903

Hi Alex!

I am wondering why PK superiority? I am not getting if you do not prove faster onset of action with PD superiority, you can have advantage. Already the discussion for Tmax assessment (EMA PSG) is discussed in forum. Could you provide more details for not focusing on PD superiority?
Regards,
Divyen Shah

Complete thread:

UA Flag
Activity
 Admin contact
23,223 posts in 4,877 threads, 1,656 registered users;
30 visitors (0 registered, 30 guests [including 6 identified bots]).
Forum time: 19:38 CEST (Europe/Vienna)

Explanations exist; they have existed for all time;
there is always an easy solution to every human problem –
neat, plausible and wrong.    H. L. Mencken

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5